Zdrowie i gospodarka · 16/05/2007

FDA Clears Path for Atovaquone Tablets, 250mg, to be Approved via Abbreviated New Drug Applications

The Food and Drug Administration (FDA) has determined that MEPRON (atovaquone) tablets, 250 milligrams, were not withdrawn from sale due to safety or efficacy concerns, paving the way for the approval of abbreviated new drug applications (ANDAs) for atovaquone tablets, 250 mg.